Adjuvant medical treatment options for cutaneous malignant melanoma;Kutanöz malign melanomda adjuvan medikal tedavi yaklaşimlari

Turk Onkoloji Dergisi

Volumn 25, Issue 4, 2010, Pages 170-180

  Öztürk, Banu ^a   Yaman, Emel ^b   Kaya, Ali Osman ^b   Yildiz, Ramazan ^b   Demirci, Umut ^b   Coşkun, Uǧur ^b   Benekli, Mustafa ^b   Büyükberber, Süleyman ^b  

^a KONYA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Adjuvant; Immunologic; Immunotherapy; Melanoma

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; EARLY CANCER; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PROGNOSIS; REVIEW; TUMOR VOLUME;

EID: 78751623634     PISSN: 13007467     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Berwick M, Halpern A. Melanoma epidemiology. Curr Opin Oncol 1997;9(2):178-82.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49.
3. Aydingoz IE, Yildiz K, Dervent B. Haydarpaşa Numune Hastanesinde 5 yillik malign melanom olgularinin deǧerlendirilmesi. [Evaluation of malignant melanoma cases during five years period at haydarpasa numune Hospital.] T Klin Dermatoloji 1998;8:130-4.
4. Akturk A, Yildiz KD, Bilen N, Bayramgürler D, Kiran R, Onyedi M. Kocaeli Üniversitesi Tip Fakültesine 1996-2003 yillari arasinda aşvuran deri kanseri olgulari. [Skin cancer cases admitted to Kocaeli University Medical Faculty between years 1996-2003.] Türkiye Klinikleri J Dermatol 2006;16:44-9.
5. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17(2):117-27.
6. Rusciani L, Proietti I, Paradisi A, Rusciani A, Guerriero G, Mammone A, et al. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up. Melanoma Res 2007;17(3):177-83.
7. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician 2000;62(2):357-68, 375-6, 381-2.
8. Lens M. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease. Dermatol Ther 2006;19(1):9-18.
9. Newby JC, Eisen T. The role of chemotherapy. In: Newton. Bishop JA, Gore M, eds. Melanoma. Critical debates. Oxford: Blackwell Science; 2002. p. 178-94.
10. Whittaker S. Adjuvant therapy in melanoma. Clin Exp Dermatol 2000;25(6):497-502.
11. Agarwala SS, Kirkwood JM. Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000;10(3):230-9.
12. Shah GD, Chapman PB. Adjuvant therapy of melanoma. Cancer J 2007;13(3):217-22.
13. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17.
14. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18(12):2444-58.
15. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16(4):1425-9.
16. Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351(9120):1905-10.
17. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358(9285):866-9.
18. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22(1):53-61.
19. Cameron DA, Cornbleet MC, Mackie RM, Hunter JA, Gore M, Hancock B, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 2001;84(9):1146-9.
20. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366(9492):1189-96.
21. Mohr P, Hauschild A, Enk A, Rass K, Grabbe S, et al. Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408). 2008 ASCO Annual Meeting (abstract no: 9040).
22. Citation: J Clin Oncol 26:2008 (May 20 suppl; abstr 9040).
23. Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, et al. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem 2006;17(1):179-88.
24. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372(9633):117-26.
25. Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009;27(18):2916-23.
26. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003;21(15):2883-8.
27. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-16.
28. Hersey P, Murray E, Grace J, McCarthy WH. Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology 1985;17(3):385-91.
29. Bröcker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988;41(4):562-7.
30. Platsoucas CD. Human autologous tumor-specific T cells in malignant melanoma. Cancer Metastasis Rev 1991;10(2):151-76.
31. Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993;53(4):566-73.
32. Livingston P. Ganglioside vaccines with emphasis on GM2. Semin Oncol 1998;25(6):636-45.
33. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995;55(13):2783-8.
34. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 2000;6(3):874-9.
35. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19(9):2370-80.
36. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001;19(5):1430-6.
37. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12(5):1036-44.
38. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 2004;100(8):1692-8.
39. Wallack MK, Steplewski Z, Koprowski H, Rosato E, George J, Hulihan B, et al. A new approach in specific, active immunotherapy. Cancer 1977;39(2):560-4.
40. Wallack MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997;226(2):198-206.
41. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20(20):4181-90.
42. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20(8):2058-66.
43. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol 2007;25(15):2078-85.
44. Eggermont AM, Suciu S, Ruka W, et al, EORTC Melanoma Group EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. 2008 ASCO Annual Meeting Abstract No:9004.
45. Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 9004).
46. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18(8):1614-21.
47. Spitler LE, Weber RW, Cruickshank S, et al. Granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) as adjuvant therapy of melanoma. 2008 ASCO Annual Meeting Abstract No: 20006.
48. Citation: J Clin Oncol 26:2008 (May 20 suppl; abstr 20006).
49. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307(15):913-6.
50. Hill GJ 2nd, Moss SE, Golomb FM, Grage TB, Fletcher WS, Minton JP, et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer 1981;47(11):2556-62.
51. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. Can Med Assoc J 1983;128(8):929-33.
52. Kretschmer L, Helmbold P, Emmert S, Marsch WC. Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma. Hautarzt 2002;53(8):536-41. [Abstract]
53. Stadler R, Luger T, Bieber T, Köhler U, Linse R, Technau K, et al. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta Oncol 2006;45(4):389-99.
54. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 2009;19(1):42-9.